These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

419 related items for PubMed ID: 9199408

  • 1. The second Kunitz domain of human tissue factor pathway inhibitor: cloning, structure determination and interaction with factor Xa.
    Burgering MJ, Orbons LP, van der Doelen A, Mulders J, Theunissen HJ, Grootenhuis PD, Bode W, Huber R, Stubbs MT.
    J Mol Biol; 1997 Jun 13; 269(3):395-407. PubMed ID: 9199408
    [Abstract] [Full Text] [Related]

  • 2. The role of catalytic cleft and exosite residues of factor VIIa for complex formation with tissue factor pathway inhibitor.
    Iakhiaev A, Ruf W, Rao LV.
    Thromb Haemost; 2001 Mar 13; 85(3):458-63. PubMed ID: 11307815
    [Abstract] [Full Text] [Related]

  • 3. Structural and functional characterization of tissue factor pathway inhibitor following degradation by matrix metalloproteinase-8.
    Cunningham AC, Hasty KA, Enghild JJ, Mast AE.
    Biochem J; 2002 Oct 15; 367(Pt 2):451-8. PubMed ID: 12117418
    [Abstract] [Full Text] [Related]

  • 4. Structure and biology of tissue factor pathway inhibitor.
    Bajaj MS, Birktoft JJ, Steer SA, Bajaj SP.
    Thromb Haemost; 2001 Oct 15; 86(4):959-72. PubMed ID: 11686353
    [Abstract] [Full Text] [Related]

  • 5. Activity of secreted Kunitz domain 1 variants of tissue factor pathway inhibitor.
    Johnson K, Zaror I, Bauer D, Choi Y, Creasey A, Innis M.
    Thromb Haemost; 1998 Oct 15; 80(4):585-7. PubMed ID: 9798974
    [Abstract] [Full Text] [Related]

  • 6. Structure of extracellular tissue factor complexed with factor VIIa inhibited with a BPTI mutant.
    Zhang E, St Charles R, Tulinsky A.
    J Mol Biol; 1999 Feb 05; 285(5):2089-104. PubMed ID: 9925787
    [Abstract] [Full Text] [Related]

  • 7. Transient high affinity binding of tissue factor pathway inhibitor-factor Xa complexes to negatively charged phospholipid membranes.
    Willems GM, Janssen MP, Salemink I, Wun TC, Lindhout T.
    Biochemistry; 1998 Mar 10; 37(10):3321-8. PubMed ID: 9521652
    [Abstract] [Full Text] [Related]

  • 8. Inhibition of factor X activation at extracellular matrix of fibroblasts during flow conditions: a comparison between tissue factor pathway inhibitor and inactive factor VIIa.
    Valentin S, Reutlingsperger CP, Nordfang O, Lindhout T.
    Thromb Haemost; 1995 Dec 10; 74(6):1478-85. PubMed ID: 8772224
    [Abstract] [Full Text] [Related]

  • 9. Cloning, expression, and characterization of mouse tissue factor pathway inhibitor (TFPI).
    Chang JY, Monroe DM, Oliver JA, Liles DK, Roberts HR.
    Thromb Haemost; 1998 Feb 10; 79(2):306-9. PubMed ID: 9493581
    [Abstract] [Full Text] [Related]

  • 10. TFPIbeta, a second product from the mouse tissue factor pathway inhibitor (TFPI) gene.
    Chang JY, Monroe DM, Oliver JA, Roberts HR.
    Thromb Haemost; 1999 Jan 10; 81(1):45-9. PubMed ID: 9974373
    [Abstract] [Full Text] [Related]

  • 11. Factor Xa cleavage of tissue factor pathway inhibitor is associated with loss of anticoagulant activity.
    Salemink I, Franssen J, Willems GM, Hemker HC, Li A, Wun TC, Lindhout T.
    Thromb Haemost; 1998 Aug 10; 80(2):273-80. PubMed ID: 9716152
    [Abstract] [Full Text] [Related]

  • 12. Nuclear magnetic resonance solution structure of the human Hsp40 (HDJ-1) J-domain.
    Qian YQ, Patel D, Hartl FU, McColl DJ.
    J Mol Biol; 1996 Jul 12; 260(2):224-35. PubMed ID: 8764402
    [Abstract] [Full Text] [Related]

  • 13. High-resolution solution NMR structure of the Z domain of staphylococcal protein A.
    Tashiro M, Tejero R, Zimmerman DE, Celda B, Nilsson B, Montelione GT.
    J Mol Biol; 1997 Oct 03; 272(4):573-90. PubMed ID: 9325113
    [Abstract] [Full Text] [Related]

  • 14. Structural requirements for tissue factor pathway inhibitor interactions with factor Xa and heparin.
    Wesselschmidt R, Likert K, Huang Z, MacPhail L, Broze GJ.
    Blood Coagul Fibrinolysis; 1993 Oct 03; 4(5):661-9. PubMed ID: 8292716
    [Abstract] [Full Text] [Related]

  • 15. Solution structure and backbone dynamics of the human alpha3-chain type VI collagen C-terminal Kunitz domain,
    Sorensen MD, Bjorn S, Norris K, Olsen O, Petersen L, James TL, Led JJ.
    Biochemistry; 1997 Aug 26; 36(34):10439-50. PubMed ID: 9265624
    [Abstract] [Full Text] [Related]

  • 16. Determination of the solution structure of Apo calbindin D9k by NMR spectroscopy.
    Skelton NJ, Kördel J, Chazin WJ.
    J Mol Biol; 1995 Jun 02; 249(2):441-62. PubMed ID: 7783203
    [Abstract] [Full Text] [Related]

  • 17. Inhibitory properties of a novel human Kunitz-type protease inhibitor homologous to tissue factor pathway inhibitor.
    Petersen LC, Sprecher CA, Foster DC, Blumberg H, Hamamoto T, Kisiel W.
    Biochemistry; 1996 Jan 09; 35(1):266-72. PubMed ID: 8555184
    [Abstract] [Full Text] [Related]

  • 18. Monoclonal antibody specific for tissue factor pathway inhibitor-factor Xa complex: its characterization and application to plasmas from patients with disseminated intravascular coagulation and pre-disseminated intravascular coagulation.
    Ohkura N, Soe G, Kohno I, Kumeda K, Wada H, Kamikubo Y, Shiku H, Kato H.
    Blood Coagul Fibrinolysis; 1999 Sep 09; 10(6):309-19. PubMed ID: 10493212
    [Abstract] [Full Text] [Related]

  • 19. Kinetics of the inhibition of tissue factor-factor VIIa by tissue factor pathway inhibitor.
    Lindhout T, Franssen J, Willems G.
    Thromb Haemost; 1995 Sep 09; 74(3):910-5. PubMed ID: 8571320
    [Abstract] [Full Text] [Related]

  • 20. The Kunitz 1 and Kunitz 3 domains of tissue factor pathway inhibitor are required for efficient inhibition of factor Xa.
    Peraramelli S, Suylen DP, Rosing J, Hackeng TM.
    Thromb Haemost; 2012 Aug 09; 108(2):266-76. PubMed ID: 22627666
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.